Approval Background

Burosumab received final approval from the European Medicines Agency (EMA) on February 19, 2018. It successfully completed the regulatory pathway for orphan drug designation within the European Union, demonstrating that it met the stringent requirements of the regulatory body.

Clinical Evidence

The approval was based on existing clinical trial data. The clinical trials demonstrated that burosumab normalizes phosphate metabolism in the body. The reliability of this data was crucial, as the approval would have been difficult to obtain without this evidence.

Market Positioning

Burosumab is considered more effective than existing adjunctive therapies due to its unique mechanism of action as an FGF23 inhibitor. Therefore, it is likely to gain a competitive advantage over other drugs in the orphan drug market.

Reimbursement and Market Outlook

The availability of reimbursement from European national healthcare systems is a key factor in market access. In some countries, limited reimbursement may restrict initial sales. However, in the long term, improved patient access could lead to market expansion.